Newly granted U.S. patent covers composition of matter claims and treatment methods in support of the Company’s CYB003 program until 2041 The post Cybin...
Cybin reports first quarter financial results and business highlights, including updates on key trials. The post Cybin Reports Q1 Financial Results and...
-Cybin Inc. (NYSE American:CYBN / NEO:CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new...
Toronto-based Cybin Inc. (NYSE: CYBN) (NEO: CYBN) increased its losses for its first fiscal quarter of 2023 to C$14.5 million, up from C$13.1 million a...
Who won the awards on the final night of the Diggers and Dealers forum in Kalgoorlie and which lithium explorer ... Read More The post Diggers...
it's important to ensure that psychedelic therapy is accessible to those who need it and is conducted in a safe and ethical manner. The post Psychedelic-Assisted...
Algernon NeuroScience has completed a feasibility study and has finalized its clinical trial design for a 40 patient Phase 2 DMT Stroke study. The post...
Cybin Inc. (NYSE American:CYBN / NEO:CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new...
Cybin Inc. (NYSE American:CYBN / NEO:CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new...
Disruptor Will Use Oversubscribed Series A Funding From Blue-Chip VCs to Further Invest in Research & Development, Build out Application Code and Pipeline...